Study guide

3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

Key Takeaways Explain This Topic AI

Therapeutic Drug Monitoring (TDM) is indicated for narrow therapeutic index drugs exhibiting high pharmacokinetic variability, direct concentration-response relationships, and absence of readily measurable clinical markers.

Aminoglycosides exhibit concentration-dependent bacterial killing; extended-interval dosing maximizes the Cmax/MIC ratio (>= 8-10) and post-antibiotic effect while allowing drug-free trough periods that minimize nephrotoxicity.

Current vancomycin consensus guidelines mandate AUC24/MIC-guided monitoring (target 400-600 mg*h/L for MIC <= 1 mg/L) via Bayesian software or two-point sampling, transitioning away from high trough targets (15-20 mg/L) to prevent acute kidney injury.

Digoxin samples must be collected at least 6 to 8 hours post-dose to allow complete tissue distribution; target concentrations are 0.5-0.9 ng/mL for heart failure and 0.8-1.5 ng/mL for atrial fibrillation.

Lithium is 100% renally eliminated and reabsorbed in the proximal tubule; thiazide diuretics, NSAIDs, and ACE inhibitors reduce lithium clearance, triggering severe neurotoxicity.

Last updated: August 2026

3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring drug concentrations in biological matrices (typically serum or plasma) at designated intervals to optimize pharmacotherapy in individual patients. By integrating pharmacokinetic principles with patient-specific pathophysiological variables, the clinical pharmacist tailors dosing regimens to achieve maximum therapeutic efficacy while avoiding concentration-dependent toxicity.

1. Principles and Criteria for Therapeutic Drug Monitoring +-------------------------------------------------------------------------------------+

  • | INDICATIONS FOR CLINICAL TDM |
  • +-------------------------------------------------------------------------------------+
  • | 1. Narrow Therapeutic Index (NTI) : Narrow margin between efficacy and toxicity |
  • | 2. High PK Inter-Patient Variation : Unpredictable dose-concentration relationship |
  • | 3. Defined Target Range : Direct correlation of level to clinical effect|
  • | 4. Lack of Direct Clinical Endpoint: Cannot titrate via BP, glucose, or INR |
  • | 5. Suspected Toxicity / Noncompliance: Clarifying adverse events or lack of response|
  • | 6. Altered Pathophysiology : Renal/hepatic failure, pregnancy, burns, sepsis|
  • +-------------------------------------------------------------------------------------+
  • Rules for Blood Sample Collection Timing

True Steady-State Sampling : Serum concentrations should generally be measured only after steady state has been attained ( ≥ 4 to 5 elimination half-lives \ge 4 \text{ to } 5 \text{ elimination half-lives} ≥ 4 to 5 elimination half-lives under a consistent dosing regimen), unless acute toxicity is suspected or early loading dose assessment is required.

Trough Concentration ( C min C_{\text{min}} C min ​ ) : Collected immediately prior to the next scheduled dose (within ≤ 30 minutes \le 30\text{ minutes} ≤ 30 minutes before dose administration). Troughs evaluate drug accumulation and clearance.

Peak Concentration ( C max C_{\text{max}} C max ​ ) : Collected after the distribution phase is fully completed:

IV Aminoglycosides : 30 minutes 30\text{ minutes} 30 minutes after completion of a 30 -minute 30\text{-minute} 30 -minute IV infusion ( 60 minutes 60\text{ minutes} 60 minutes post-infusion start).

IV Vancomycin : 1 to 2 hours 1 \text{ to } 2\text{ hours} 1 to 2 hours post-infusion completion (to avoid distribution-phase artifacts).

Oral Digoxin : ≥ 6 to 8 hours \ge 6 \text{ to } 8\text{ hours} ≥ 6 to 8 hours post-dose (mandated by its extensive, slow multi-compartment tissue distribution).

Oral Lithium : 12 hours 12\text{ hours} 12 hours post-evening dose (standardized 12-hour trough).

2. Aminoglycoside Antibiotics (Gentamicin, Tobramycin, Amikacin)

Aminoglycosides are bactericidal antibiotics that bind the bacterial 30S ribosomal subunit. They are renally eliminated via glomerular filtration ( C L renal ≈ G F R CL_{\text{renal}} \approx GFR C L renal ​ ≈ GFR ) and distribute into extracellular body water ( V d ≈ 0.25 − 0.30 L/kg V_d \approx 0.25 - 0.30\text{ L/kg} V d ​ ≈ 0.25 − 0.30 L/kg in non-critically ill adults; elevated to 0.4 − 0.5 L/kg 0.4 - 0.5\text{ L/kg} 0.4 − 0.5 L/kg in sepsis, ascites, or severe burns). +-------------------------------------------------------------------------------------+

  • | AMINOGLYCOSIDE PK/PD AND DOSING PARADIGMS |
  • +-------------------------------------------------------------------------------------+
  • | PK/PD Target: Concentration-Dependent Killing + Post-Antibiotic Effect (PAE) |
  • | Target Peak / MIC ratio >= 8 to 10 |
  • | |
  • | Extended-Interval Dosing (Once-Daily): |
  • | - Dose: 5 to 7 mg/kg IV q24h (Gentamicin/Tobramycin); 15 mg/kg IV q24h (Amikacin) |
  • | - High Cmax -> Optimal bacterial killing; Prolonged Trough <0.5 mg/L -> Low tox |
  • | - Monitored via Hartford Nomogram (random level drawn 6-14 hours post-dose) |
  • | |
  • | Conventional Multi-Dose Dosing (q8h): |
  • | - Peak Target: 5 - 10 mg/L (Gram-negative sepsis/pneumonia); 3 - 5 mg/L (Synergy) |
  • | - Trough Target: < 1 - 2 mg/L (< 0.5 - 1.0 mg/L preferred) |
  • | |
  • | Toxicities: |
  • | - Nephrotoxicity: Non-oliguric ATN; saturable proximal tubule uptake; reversible. |
  • | - Ototoxicity : Vestibular/cochlear hair cell apoptosis; AUC-driven; irreversible|
  • +-------------------------------------------------------------------------------------+
  • Hartford Nomogram for Extended-Interval Aminoglycoside Dosing

Following a 7 mg/kg 7\text{ mg/kg} 7 mg/kg IV infusion of gentamicin or tobramycin, a single serum concentration is measured between 6 and 14 hours 6 \text{ and } 14\text{ hours} 6 and 14 hours post-dose start. The concentration is plotted on the nomogram to determine the appropriate dosing interval:

Below the q 24 h q24h q 24 h line: Administer every 24 hours 24\text{ hours} 24 hours .

Between q 24 h q24h q 24 h and q 36 h q36h q 36 h lines: Administer every 36 hours 36\text{ hours} 36 hours .

Between q 36 h q36h q 36 h and q 48 h q48h q 48 h lines: Administer every 48 hours 48\text{ hours} 48 hours .

Above the q 48 h q48h q 48 h line: Stop therapy, wait for concentration to fall < 1 mg/L < 1\text{ mg/L} < 1 mg/L , and monitor renal function.

3. Vancomycin Glycopeptide Antibiotic

Vancomycin binds the D-Ala-D-Ala terminus of bacterial cell wall peptidoglycan precursors, inhibiting cell wall synthesis in Gram-positive organisms, notably methicillin-resistant Staphylococcus aureus (MRSA). +-------------------------------------------------------------------------------------+

  • | VANCOMYCIN TDM CONSENSUS GUIDELINES |
  • +-------------------------------------------------------------------------------------+
  • | Primary PK/PD Parameter: AUC24 / MIC ratio >= 400 to 600 mg*h/L |
  • | (assuming broth microdilution MIC <= 1 mg/L) |
  • | |
  • | Monitoring Methods: |
  • | 1. Bayesian PK Software Estimation (Preferred: based on 1 or 2 timed levels) |
  • | 2. Two-Point PK Calculation: Peak (1-2h post-infusion) + Trough (pre-next dose) |
  • | |
  • | Old Paradigm (Trough-Only 15-20 mg/L) : Associated with 3-4x higher risk of AKI; |
  • | NO LONGER RECOMMENDED for serious MRSA. |
  • | |
  • | Toxicities: |
  • | - Nephrotoxicity : Acute tubular necrosis; risk spikes with troughs >15-20 mg/L |
  • | and co-administration of piperacillin-tazobactam / aminoglycos. |
  • | - Vancomycin Infusion Reaction ("Red Man"): Non-IgE histamine release from rapid |
  • | infusion (>1 g/hr); managed by infusing over >=1.5-2 hours. |
  • +-------------------------------------------------------------------------------------+
  • Two-Point PK Determination of Vancomycin AUC

When Bayesian software is unavailable, two serum concentrations are drawn at steady state:

C peak C_{\text{peak}} C peak ​ : Drawn 1 to 2 hours 1 \text{ to } 2\text{ hours} 1 to 2 hours after completion of the IV infusion.

C trough C_{\text{trough}} C trough ​ : Drawn within 30 minutes 30\text{ minutes} 30 minutes prior to the next dose. Elimination Rate Constant ( k e ) = ln ⁡ ( C peak / C trough ) Δ t \text{Elimination Rate Constant } (k_e) = \frac{\ln(C_{\text{peak}} / C_{\text{trough}})}{\Delta t} Elimination Rate Constant ( k e ​ ) = Δ t ln ( C peak ​ / C trough ​ ) ​ True Peak at End of Infusion ( C max ) = C peak e − k e ⋅ t wait \text{True Peak at End of Infusion } (C_{\text{max}}) = \frac{C_{\text{peak}}}{e^{-k_e \cdot t_{\text{wait}}}} True Peak at End of Infusion ( C max ​ ) = e − k e ​ ⋅ t wait ​ C peak ​ ​ True Trough ( C min ) = C trough ⋅ e − k e ⋅ t rem \text{True Trough } (C_{\text{min}}) = C_{\text{trough}} \cdot e^{-k_e \cdot t_{\text{rem}}} True Trough ( C min ​ ) = C trough ​ ⋅ e − k e ​ ⋅ t rem ​ AUC infusion = Dose T inf ⋅ k e ⋅ ( 1 − e − k e ⋅ T inf C max ) \text{AUC}_{\text{infusion}} = \frac{\text{Dose}}{T_{\text{inf}} \cdot k_e} \cdot \left(\frac{1 - e^{-k_e \cdot T_{\text{inf}}}}{C_{\text{max}}}\right) AUC infusion ​ = T inf ​ ⋅ k e ​ Dose ​ ⋅ ( C max ​ 1 − e − k e ​ ⋅ T inf ​ ​ ) Daily AUC 24 = AUC interval ⋅ ( 24 τ ) \text{Daily AUC}_{24} = \text{AUC}_{\text{interval}} \cdot \left(\frac{24}{\tau}\right) Daily AUC 24 ​ = AUC interval ​ ⋅ ( τ 24 ​ )

4. TDM of Cardiovascular and Neurologic Agents

Drug Target Therapeutic Range Standard Sampling Time Major Toxicities & High Levels Critical Interactions & Clinical Nuances

Digoxin Heart Failure :; 0.5 − 0.9 ng/mL 0.5 - 0.9\text{ ng/mL} 0.5 − 0.9 ng/mL ; ( 0.6 − 1.2 nmol/L 0.6 - 1.2\text{ nmol/L} 0.6 − 1.2 nmol/L ); ; Atrial Fibrillation :; 0.8 − 1.5 ng/mL 0.8 - 1.5\text{ ng/mL} 0.8 − 1.5 ng/mL ; ( 1.0 − 1.9 nmol/L 1.0 - 1.9\text{ nmol/L} 1.0 − 1.9 nmol/L ) ≥ 6 − 8 hours \ge 6 - 8\text{ hours} ≥ 6 − 8 hours post-dose (trough immediately pre-dose preferred) > 2.0 ng/mL > 2.0\text{ ng/mL} > 2.0 ng/mL ( > 2.6 nmol/L > 2.6\text{ nmol/L} > 2.6 nmol/L ): Anorexia, nausea, yellow-green visual halos (xanthopsia), bidirectional VT, AV block. Electrolyte Sensitizers : Hypokalemia, hypomagnesemia, and hypercalcemia potentate digoxin cardiotoxicity at normal serum levels. P-gp inhibitors (amiodarone, verapamil, quinidine) reduce clearance by 50 % 50\% 50% (mandating empiric 50 % 50\% 50% digoxin dose cut). Antidote : Digoxin Immune Fab.

Phenytoin Total :; 10 − 20 mg/L 10 - 20\text{ mg/L} 10 − 20 mg/L ; ( 40 − 80 μ mol/L 40 - 80\text{ }\mu \text{mol/L} 40 − 80 μ mol/L ); ; Free (Unbound) :; 1 − 2 mg/L 1 - 2\text{ mg/L} 1 − 2 mg/L ; ( 4 − 8 μ mol/L 4 - 8\text{ }\mu \text{mol/L} 4 − 8 μ mol/L ) Trough (immediately prior to next dose) > 20 mg/L > 20\text{ mg/L} > 20 mg/L : Nystagmus; > 30 mg/L > 30\text{ mg/L} > 30 mg/L : Ataxia, slurred speech; > 40 mg/L > 40\text{ mg/L} > 40 mg/L : Lethargy, coma, paradoxical seizures. Non-linear Michaelis-Menten kinetics ( V max , K m V_{\text{max}}, K_m V max ​ , K m ​ ). High protein binding ( 90 % 90\% 90% to albumin). Hypoalbuminemia requires Winter-Tozer correction or direct free level measurement. CYP2C9 inducers/inhibitors alter levels drastically.

Lithium Acute Mania :; 0.8 − 1.2 mmol/L 0.8 - 1.2\text{ mmol/L} 0.8 − 1.2 mmol/L (mEq/L); ; Maintenance :; 0.6 − 0.8 mmol/L 0.6 - 0.8\text{ mmol/L} 0.6 − 0.8 mmol/L (Elderly: 0.4 − 0.6 0.4 - 0.6 0.4 − 0.6 ) Exactly 12 hours 12\text{ hours} 12 hours post-evening dose (12-hour trough) > 1.5 mmol/L > 1.5\text{ mmol/L} > 1.5 mmol/L : Coarse tremor, vomiting, diarrhea, ataxia; > 2.0 mmol/L > 2.0\text{ mmol/L} > 2.0 mmol/L : Hyperreflexia, clonus, delirium; > 2.5 − 3.0 mmol/L > 2.5 - 3.0\text{ mmol/L} > 2.5 − 3.0 mmol/L : Seizures, coma, acute renal failure. Excreted 100 % 100\% 100% by kidneys; reabsorbed in proximal tubule like sodium. Toxicity Triggers : Thiazide diuretics, NSAIDs, ACE inhibitors, ARBs, sodium restriction, dehydration. Dialysis : Indicated if > 4.0 mmol/L > 4.0\text{ mmol/L} > 4.0 mmol/L (or > 2.5 mmol/L > 2.5\text{ mmol/L} > 2.5 mmol/L with severe symptoms/renal failure).

Theophylline 5 − 15 mg/L 5 - 15\text{ mg/L} 5 − 15 mg/L ; ( 28 − 83 μ mol/L 28 - 83\text{ }\mu \text{mol/L} 28 − 83 μ mol/L ); (Aminophylline = 80 − 85 % 80-85\% 80 − 85% theophylline base) Trough for oral slow-release; steady-state infusion > 20 mg/L > 20\text{ mg/L} > 20 mg/L : Nausea, tachycardia, insomnia; > 30 mg/L > 30\text{ mg/L} > 30 mg/L : Ventricular arrhythmias, intractable status epilepticus. Metabolized by CYP1A2. Induction : Tobacco/cannabis smoking increases clearance (higher dose required; smoking cessation triggers toxicity). Inhibition : Ciprofloxacin, fluvoxamine, clarithromycin cause severe toxicity.